Table 3.
Correlation between daily insulin dose (IU, median) and HbA1c levels stratified according to the therapeutic regimen.
| HbA1c | Insulin glargine only (n = 158) | Insulin glargine plus other oral glucose-lowering drugs (n = 901) | Insulin glargine plus DPP-4 inhibitors (n = 249) | Insulin glargine plus rapid-acting insulin (n = 2,097) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients with HbA1c value (%) | Daily dose (IU) | Patients with HbA1c value (%) | Daily dose (IU) | Patients with HbA1c value (%) | Daily dose (IU) | Patients with HbA1c value (%) | Daily dose (IU) | |||||
| Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | |||||
| <7% | 53.8 | 42.4 (35.1) | 35.7 (37.5) | 29.3% | 34.1 (40.1) | 20.9 (38.5) | 34.1% | 39.9 (32.4) | 43.0 (37.2) | 28.8^ | 40.4 (34.2) | 20.9 (35.8)° |
| 7-8% | 19.6 | 32.6 (33.9) | 15.3 (42.7) | 35.2% | 30.3 (39.3) | 16.6 (29.2) | 34.5% | 34.0 (33.6) | 19.7 (39.8) | 35.1^ | 30.3 (46.7) | 19.9 (24.5) |
| 8-9% | 13.9 | 34.6 (34.3) | 18.7 (38.4) | 19.1% | 26.5 (32.7) | 16.7 (22.2) | 21.7% | 30.6 (28.3) | 17.1 (38.9) | 22.2^ | 30.0 (34.4) | 20.4 (23.8) |
| >9% | 12.7 | 35.6 (27.7) | 28.5 (36.9) | 16.4% | 30.7 (34.4) | 18.2 (32.5) | 9.6% | 28.0 (26.0) | 19.2 (27.8) | 14.0^ | 29.5 (23.0) | 22.7 (24.3) |
The analysis was carried out on the cohort of patients for which the laboratory data were available and with at least 3 months of follow-up. ^p < 0.05 among groups. °p < 0.05 among groups.